Taconic Biosciences Sustainability Profile
Taconic Biosciences, a leading provider of genetically engineered rodent models, is headquartered in the United States, with significant operations across Europe and Asia. Founded in 2007, the company has established itself as a key player in the biotechnology industry, focusing on preclinical research and model development for drug discovery and development. Taconic's core offerings include custom mouse models, biorepositories, and advanced breeding services, all designed to meet the specific needs of researchers in academia and the pharmaceutical sector. What sets Taconic apart is its commitment to quality and innovation, ensuring that their models are not only reliable but also tailored to the unique requirements of each project. With a strong market position, Taconic Biosciences has achieved notable milestones, including partnerships with leading pharmaceutical companies and contributions to significant scientific advancements. Their dedication to excellence continues to drive their reputation as a trusted resource in the field of biomedical research.
DitchCarbon Score
How does Taconic Biosciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Taconic Biosciences's score of 23 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Taconic Biosciences's reported carbon emissions
Taconic Biosciences, headquartered in the United States, currently does not report any specific carbon emissions data for the most recent year. However, the company is committed to addressing climate change through various initiatives. Taconic has made a near-term commitment to reduce its carbon footprint, although it has not set a net-zero target or defined long-term reduction goals. As part of its climate strategy, Taconic is classified under the Pharmaceuticals, Biotechnology, and Life Sciences sector. The company is actively engaged in sustainability efforts, aligning with industry standards and practices. While specific emissions figures are not available, Taconic's commitment to reducing its environmental impact reflects a growing trend within the industry to prioritise climate action. The emissions data and climate commitments are not cascaded from any parent organisation, indicating that Taconic is independently managing its sustainability initiatives. The company continues to explore opportunities for improvement in its environmental performance.
How Carbon Intensive is Taconic Biosciences's Industry?
How Carbon Intensive is Taconic Biosciences's Location?
Taconic Biosciences's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Taconic Biosciences has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
